drugset / Trial / NCT02121756
Dipyridamole for Immune Activation in HIV
Phase 1/2
Completed
40 enrolled
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
Timeline
- Start
- 2014-07
- Primary completion
- 2017-10
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipyridamole | Other / unclassified | 100 mg | — |